Table 2.
High-risk factors of breast cancer brain metastasis
| Item |
Univariate Cox
|
Multivariate Cox
|
||
|
HR (95%CI)
|
P
|
HR (95%CI)
|
P | |
| Age at diagnosis of BC (yr) | ||||
| ≤ 35 | Reference | |||
| > 35 | 0.008 (0-1.89) | 0.083 | ||
| Menstrual status at diagnosis of BC | ||||
| Premenopause | Reference | |||
| Menopause | 1.29 (0.52-3.20) | 0.59 | ||
| Family history of cancer | ||||
| None | Reference | |||
| Yes | 0.62 (0.26-1.44) | 0.26 | ||
| Lymph node stage | ||||
| N0-N1 | Reference | |||
| N2-N3 | 2.77 (1.40-5.48) | 0.004 | NS | |
| Tumor size | ||||
| T1-T2 | Reference | |||
| T3-T4 | 1.44 (0.65-3.15) | 0.37 | ||
| Tumor stage at the initial diagnosis | ||||
| I-II | Reference | |||
| III-IV | 3.84 (1.89-7.78) | < 0.001 | 5.58 (1.99-15.68) | 0.001 |
| ER | ||||
| Negative | Reference | |||
| Positive | 0.49 (0.27-0.87) | 0.015 | NS | |
| PR | ||||
| Negative | Reference | |||
| Positive | 0.36 (0.18-0.69) | 0.002 | NS | |
| Molecular type | ||||
| Luminal A type | Reference | |||
| Luminal B type | 3.95 (1.71-9.14) | 0.001 | 5.36 (1.61-17.76) | 0.006 |
| HER2-overexpression type | 4.01 (1.61-9.96) | 0.003 | 5.0 (1.30-19.25) | 0.019 |
| Triple-negative type | 4.34 (1.55-12.11) | 0.005 | NS | NS |
| Pathological type | ||||
| Others | Reference | |||
| Invasive ductal carcinoma | 1.83 (0.83-4.05) | 0.14 | ||
| Invasive lobular carcinoma | 1.31 (0.22-7.69) | 0. 77 | ||
| Surgical treatment | ||||
| Others | Reference | |||
| Modified radical mastectomy | 0.48 (0.26-0.90) | 0.021 | NS | |
| Bone metastasis | ||||
| No | Reference | |||
| Yes | 7.19 (3.13-16.52) | < 0.001 | NS | |
| Liver metastasis | ||||
| No | Reference | |||
| Yes | 7.44 (2.77-20.01) | < 0.001 | NS | |
| Lung metastasis | ||||
| No | Reference | |||
| Yes | 15.87 (5.61-44.89) | < 0.001 | 24.18 (6.40-91.43) | < 0.001 |
| Number of liver, lung and bone metastases | ||||
| < 2 | Reference | |||
| ≥ 2 | 17.78 (5.38-58.73) | < 0.001 | NS | |
| Number of metastases to other sites | ||||
| < 2 | Reference | |||
| ≥ 2 | 7.33 (2.05-26.27) | 0.002 | NS | |
95%CI: 95% confidence interval; NS: Not statistically significant; HR: Hazard ratio; ER: Estrogen receptor; PR: Progesterone receptor; BC: Breast Cancer; HER2: Human epidermal growth factor receptor 2.